The authors showed that the most potent CDK-TCIPs exhibited subnanomolar cytotoxicity in BCL6-driven DLBCL cells, achieving approximately 100 times greater potency than the combined effect of traditional inhibitors of CDK9 and BCL6. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.